Stellar Pharmaceuticals, Inc. (SLXCF.OB) Signs Licensing Agreement with medac GmbH
Canadian pharmaceutical developer Stellar Pharmaceuticals Inc. reported that they signed a licensing agreement with medac GmbH for the distribution and sale of one of its lead products, Uracyst®. The product, a sterile sodium chondrotin solution used to treat interstitial cystitis/painful bladder syndrome, will be marketed in Germany and Austria; there, the product is trademarked as Uropol®. With the approved CE mark for the product already in place, the company expects that medac will launch Uropol® in the third quarter of 2010. The agreement has an initial five-year term with additional two-year renewal periods, and under the terms of the agreement,…